Objective To evaluate the efficacy of pulse low-dose rate(PLDR)combined with bevacizumab and temozolomide in the treatment of recurrent glioblastoma.Methods Fifty-one patients with recurrent glioma after postoperative radiotherapy admitted to the Department of Tumor Radiotherapy,First Affiliated Hospital of University of Science and Technology of China from March 2020 to December 2022 were analyzed retrospectively,including 24 patients in the experimental group treated with PLDR combined with bevacizumab and temozolomide,and 27 patients in the control group treated with bevacizumab and temozolomide.PLDR radiotherapy regimen consisted of a prescription dose of DT 50-54 Gy,2 Gy/dose,divided into 10 pulse radiation,with the pulse interval time of 3 minutes,a dose rate of 0.067 Gy/min,and a single treatment duration of 30 minutes.Peripheral blood CD4+and CD8+T lymphocyte levels were measured before and after radiotherapy.One month after radiotherapy,head magnetic resonance imaging(MRI)was performed to evaluate the regression of recurrent lesions,and patients were evaluated every 3 months thereafter.Results Compared with the chemotherapy group alone,progression free survival(PFS)was significantly improved by PLDR+temozolomide(7.9 months vs 5.9 months,P<0.05).The combined regimen did not significantly increase the incidence of side effects of secondary radiation.The proportion of CD4+T cells(42.62%vs 33.31%,P<0.05)and CD8+T cells(38.53%vs 26.25%,P<0.05)in the peripheral blood of patients in the experimental group was significantly increased.Conclusions The application of PLDR combined with temozolomide in patients of recurrent glioma post-surgery and radiotherapy can improve therapeutic efficacy and activate the immune response of patients.
国家科技期刊平台
NSTL
万方数据
